You are viewing: France Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The France Plasma Fractionation Market was valued at $1264.3 Million in 2026 and projected to reach to $1786.5 Million by 2031, representing a compound annual growth rate of 7.2%. France's plasma fractionation market is poised for steady growth through 2031, supported by an aging population with rising immunological disorders and chronic disease prevalence.

France Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Plasma Fractionation Market Trends and Insights

  • France maintains a significant position within the European plasma fractionation landscape, driven by robust healthcare infrastructure, strong regulatory frameworks, and increasing demand for immunoglobulin and clotting factor therapies.
  • The French market benefits from established plasma collection networks and a growing patient population requiring plasma-derived therapeutics. During the forecast period from 2026 to 2031, France is expected to experience steady market expansion supported by rising prevalence of immunodeficiency disorders, hemophilia, and thrombotic conditions.
  • France's commitment to self-sufficiency in plasma supply and investment in fractionation capacity will further accelerate market growth.
  • Additionally, France's participation in European Union regulatory harmonization and reimbursement policies creates a favorable environment for plasma fractionation product adoption and innovation..

Key Market Statistics

  • CAGR (2026-2031) 7.2% CAGR
  • Market Size, 2026 ~USD 1264.3 Million
  • Forecast, 2031 ~USD 1786.5 Million
  • Country France

France Plasma Fractionation Market Overview

Market Size & Growth :

France's plasma fractionation market is valued at USD 1,264.3 million in 2026, expanding to USD 1,786.5 million by 2031 at a CAGR of 7.2%, outpacing many European counterparts.

Healthcare Infrastructure Strength :

France's advanced healthcare system, universal coverage, and high per capita spending support robust demand for plasma-derived therapies and immunoglobulin products across hospitals and specialty clinics.

Regulatory Excellence :

Strong regulatory frameworks aligned with EMA standards ensure product quality and safety, attracting major pharmaceutical manufacturers and fostering innovation in plasma fractionation technologies.

Immunoglobulin Demand Surge :

Rising prevalence of immunodeficiency disorders, autoimmune diseases, and aging population demographics drive increasing consumption of intravenous and subcutaneous immunoglobulin therapies in France.

France Plasma Fractionation Market Dynamics

  • The country's commitment to healthcare innovation and reimbursement policies favoring plasma-derived therapies create a favorable environment for market expansion.
  • Increased adoption of subcutaneous immunoglobulin treatments and home-based therapies will further accelerate market penetration across French healthcare settings. Key growth drivers include enhanced diagnostic capabilities, improved patient awareness, and strategic investments by major plasma collection and fractionation companies.
  • France's position within the European Union ensures access to a stable supply chain and regulatory harmonization.
  • Continued focus on rare disease treatment and personalized medicine will sustain demand for specialized plasma fractionation products through the forecast period..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • France's plasma fractionation market is valued at USD 1,264.3 million in 2026 and will reach USD 1,786.5 million by 2031 at a 7.2% CAGR.
      • France benefits from established plasma collection infrastructure and strong regulatory oversight that support market stability and product quality.
      • Rising incidence of immunodeficiency and hemophilia disorders in France is driving demand for plasma-derived immunoglobulins and clotting factors.
      • France's EU membership and harmonized reimbursement policies create favorable conditions for plasma fractionation product market penetration and growth.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      France Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical Manufacturers : Plasma fractionation companies and biopharmaceutical firms need France-specific market data to optimize product portfolios, pricing strategies, and commercial operations in this key European market.
      • Healthcare Providers & Hospitals : French hospital networks and specialty clinics require market insights to forecast immunoglobulin demand, budget for plasma-derived therapies, and plan procurement strategies.
      • Plasma Collection Organizations : Blood banks and plasma collection centers in France need market forecasts to guide facility expansion, donor recruitment initiatives, and fractionation capacity planning.
      • Investment & Private Equity Firms : Investors evaluating opportunities in French healthcare and plasma fractionation require detailed market sizing and growth projections to assess investment returns and portfolio fit.
      • Healthcare Policy & Government Bodies : French health authorities and policy makers need market data to inform reimbursement policies, healthcare budgeting, and strategic planning for rare disease and immunodeficiency treatment programs.

      Reasons to Buy this Report

      • Country-Specific Market Sizing : Obtain precise market valuations for France (2026-2031) with detailed CAGR analysis, enabling accurate budget allocation and revenue forecasting for French market operations.
      • Regulatory & Reimbursement Insights : Understand France's unique regulatory landscape, EMA compliance requirements, and reimbursement policies that directly impact product pricing, market access, and profitability strategies.
      • Competitive Landscape Analysis : Identify key players, market share distribution, and competitive positioning specific to France, supporting strategic partnership and market entry decisions.
      • Demand Driver Intelligence : Analyze France-specific factors including aging demographics, disease prevalence, healthcare spending patterns, and patient adoption trends driving plasma fractionation demand.
      • Investment & Expansion Planning : Leverage France-focused market data to evaluate expansion opportunities, facility investments, and resource allocation for plasma collection centers and distribution networks.

      Frequently asked questions

      What is the current size of France's plasma fractionation market?

      France's plasma fractionation market is estimated at USD 1,264.3 million in 2026.

      What is the projected market size for France's plasma fractionation sector by 2031?

      France's plasma fractionation market is projected to reach USD 1,786.5 million by 2031.

      What is the expected growth rate for France's plasma fractionation market?

      France's plasma fractionation market is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2026 to 2031.

      What factors are driving growth in France's plasma fractionation market?

      Growth in France's plasma fractionation market is driven by rising prevalence of immunodeficiency disorders, hemophilia, established plasma collection networks, strong regulatory frameworks, and EU reimbursement harmonization.

      How does France's plasma fractionation market compare to other European markets?

      France maintains a significant position within the European plasma fractionation landscape due to its robust healthcare infrastructure, established plasma supply networks, and commitment to self-sufficiency in plasma-derived therapeutics.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status